Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Fentanyl (compound)

Summary
General Info

PubChem

PubChem Compound 10247155

PubChem Compound 10247155

Name:	Fentanyl
PubChem Compound ID:	10247155
Description:	A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
Molecular formula:	C₂₂H₂₈N₂O
Molecular weight:	348.426 g/mol

DrugBank

Identification

Name:	Fentanyl
Name (isomeric):	DB00813
Drug Type:	small molecule
Description:	A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
Synonyms:	Fentanila [INN-Spanish]; Fentanylum [INN-Latin]; Fentanyl citrate
Brand:	Phentanyl, Nasalfent, Fentanest, Sentonil, Duragesic, Actiq, Rapinyl, Durogesic, Sublimaze, Pentanyl, Duragesic-100, Fentanil
Brand name mixture:	Innovar Injection(droperidol + fentanyl citrate)
Category:	Anesthetics, Intravenous, Adjuvants, Anesthesia, Anesthetics, Narcotics, Adjuvants, Analgesics, Opiate Agonists, Analgesics, Opioid
CAS number:	437-38-7

Pharmacology

Indication:	For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.
Pharmacology:	Fentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor but also binds to kappa and delta-type opioid receptors. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous ... show more » Fentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor but also binds to kappa and delta-type opioid receptors. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Fentanyl may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. show less «
Mechanism of Action:	Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface ... show more » Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Fentanyl's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. show less «
Absorption:	Bioavailability is 92% following transdermal administration and 50% following buccal administration.
Protein binding:	80-85%
Biotransformation:	Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system.
Route of elimination:	Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system and mostly eliminated in urine. Within 72 hours of IV fentanyl administration, approximately 75% of the dose is excreted in urine, mostly as metabolites with less than 10% representing unchanged drug.
Half Life:	7 (range 3-12) hours
Clearance:	27 – 75 L/h [Surgical Patients receving IV administration] 3 – 80 L/h [Hepatically Impaired Patients receving IV administration] 30 – 78 L/h [Renally Impaired Patients receving IV administration]
Toxicity:	Fentanyl has an LD50 of 3.1 milligrams per kilogram in rats, and, 0.03 milligrams per kilogram in monkeys. The LD50 in humans is not known.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Avoid alcohol.

Drug interaction:

Saquinavir	The protease inhibitor, saquinavir, may increase the effect and toxicity of fentanyl.
Amiodarone	Possible bradycardia, hypotension
Cimetidine	Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of fentanyl. Closely monitor changes in the therapeutic and adverse effects of fentanyl if cimetidine is initiated, discontinued or dose changed.
Telithromycin	Telithromycin may reduce clearance of Fentanyl. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fentanyl if Telithromycin is initiated, discontinued or dose changed.
Fluconazole	Fluconazole may increase levels/toxicity of fentanyl.

Saquinavir	The protease inhibitor, saquinavir, may increase the effect and toxicity of fentanyl.
Amiodarone	Possible bradycardia, hypotension
Cimetidine	Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of fentanyl. Closely monitor changes in the therapeutic and adverse effects of fentanyl if cimetidine is initiated, discontinued or dose changed.
Telithromycin	Telithromycin may reduce clearance of Fentanyl. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fentanyl if Telithromycin is initiated, discontinued or dose changed.
Fluconazole	Fluconazole may increase levels/toxicity of fentanyl.
Bicalutamide	CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of fentanyl. The risk of prolonged adverse effects, including potentially fatal respiratory depression is increased. Consider therapy modification.
Ritonavir	Ritonavir increases the effect and toxicity of fentanyl/alfentanyl
Indinavir	The protease inhibitor, indinavir, may increase the effect and toxicity of fentanyl.
Triprolidine	The CNS depressants, Triprolidine and Fentanyl, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Tranylcypromine	Possible increased risk of serotonin syndrome.
Conivaptan	CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.
Fosamprenavir	The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fentanyl.
Itraconazole	Itraconazole may increase levels/toxicity of fentanyl.
Ketoconazole	Ketoconazole may increase levels/toxicity of fentanyl.
Clotrimazole	CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.
Rifampin	Rifampin may decrease the serum level and therapeutic effect of fentanyl.
Amprenavir	The protease inhibitor, amprenavir, may increase the effect and toxicity of fentanyl.
Nelfinavir	The protease inhibitor, nelfinavir, may increase the effect and toxicity of fentanyl.
Voriconazole	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fentanyl by decreasing its metabolism. Adverse effects include life-threatening respiratory depression. Monitor for changes in the therapeutic and adverse effects of fentanyl if voriconazole is initiated, discontinued or dose changed.

Targets

Mu-type opioid receptor

Delta-type opioid receptor

Kappa-type opioid receptor

Enzymes

Cytochrome P450 3A4

Cytochrome P450 3A5

Cytochrome P450 3A7

Transporters

Multidrug resistance protein 1